Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis

Open access
Kitagawa, Kazuo, Yamamoto, Yasumasa, Arima, Hisatomi, Maeda, Toshiki, Sunami, Norio, Kanzawa, Takao, Eguchi, Kazuo, Kamiyama, Kenji, Minematsu, Kazuo, Ueda, Shinichiro, Rakugi, Hiromi, Ohya, Yusuke, Kohro, Takahide, Yonemoto, Koji, Okada, Yasushi, Higaki, Jitsuo, Tanahashi, Norio, Kimura, Genjiro, Umemura, Satoshi, Matsumoto, Masayasu, Shimamoto, Kazuaki, Ito, Sadayoshi, Saruta, Takao, Shimada, Kazuyuki, for the Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group · 2019 · JAMA Neurology

Abstract

IMPORTANCE: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that a systolic blood pressure (BP) target less than 120 mm Hg was superior to less than 140 mm Hg for preventing vascular events. This trial excluded patients with prior stroke; therefore, the ideal BP target for secondary stroke prevention remains unknown. OBJECTIVE: To assess whether intensive BP control would achieve fewer recurrent strokes vs standard BP control. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial (RCT) of standard vs intensive BP control in an intent-to-treat population of patients who had a history of stroke. Patients were enrolled between October 20, 2010, and December 7, 2016. For an updated meta-analysis, PubMed and the Cochrane Central Library database were searched through September 30, 2018, using the Medical Subject Headings and relevant search terms for cerebrovascular disease and for intensive BP lowering. This was a multicenter trial that included 140 hospitals in Japan; 1514 patients who had a history of stroke within the previous 3 years were approached, but 234 refused to give informed consent. INTERVENTIONS: In total, 1280 patients were randomized 1:1 to BP control to less than 140/90 mm Hg (standard treatment) (n = 640) or to less than 120/80 mm Hg (intensive treatment) (n = 640). However, 17 patients never received intervention; therefore, 1263 patients assigned to standard treatment (n = 630) or intensive treatment (n = 633) were analyzed. MAIN OUTCOMES AND MEASURES: The primary outcome was stroke recurrence. RESULTS: The trial was stopped early. Among 1263 analyzed patients (mean [SD] age, 67.2 [8.8] years; 69.4% male), 1257 of 1263 (99.5%) completed a mean (SD) of 3.9 (1.5) years of follow-up. The mean BP at baseline was 145.4/83.6 mm Hg. Throughout the overall follow-up period, the mean BP was 133.2/77.7 (95% CI, 132.5-133.8/77.1-78.4) mm Hg in the standard group and 126.7/77.4 (95% CI, 125.9-127.2/73.8-75.0) mm Hg in the intensive group. Ninety-one first recurrent strokes occurred. Nonsignificant rate reductions were seen for recurrent stroke in the intensive group compared with the standard group (hazard ratio [HR], 0.73; 95% CI, 0.49-1.11; P = .15). When this finding was pooled in 3 previous relevant RCTs in a meta-analysis, the risk ratio favored intensive BP control (relative risk, 0.78; 95% CI, 0.64-0.96; P = .02; absolute risk difference, -1.5%; 95% CI, -2.6% to -0.4%; number needed to treat, 67; 95% CI, 39-250). CONCLUSIONS AND RELEVANCE: Intensive BP lowering tended to reduce stroke recurrence. The updated meta-analysis supports a target BP less than 130/80 mm Hg in secondary stroke prevention. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01198496.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2019.2167

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 14

  1. Staessen, 2001, Cardiovascular protection and blood pressure reduction: a meta-analysis., Lancet, 358, 1305, 10.1016/S0140-6736(01)06411-X · DOI · Paper page
  2. Gueyffier, 1997, Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence., Stroke, 28, 2557, 10.1161/01.STR.28.12.2557 · DOI · Paper page
  3. Liu, 2009, Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature., Hypertens Res, 32, 1032, 10.1038/hr.2009.139 · DOI · Paper page
  4. Rashid, 2003, Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review., Stroke, 34, 2741, 10.1161/01.STR.0000092488.40085.15 · DOI · Paper page
  5. Katsanos, 2017, Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials., Hypertension, 69, 171, 10.1161/HYPERTENSIONAHA.116.08485 · DOI · Paper page
  6. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies., Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  7. Arima, 2006, Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial., J Hypertens, 24, 1201, 10.1097/01.hjh.0000226212.34055.86 · DOI · Paper page
  8. Benavente, 2013, Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial., Lancet, 382, 507, 10.1016/S0140-6736(13)60852-1 · DOI · Paper page
  9. Zonneveld, 2018, Blood pressure–lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack., Cochrane Database Syst Rev, 7
  10. Mant, 2016, Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke–Blood Pressure) randomised controlled trial., BMJ, 352, i708, 10.1136/bmj.i708 · DOI
  11. Bath, 2017, Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot “Prevention of Decline in Cognition After Stroke Trial” (PODCAST) randomised controlled trial., PLoS One, 12, 10.1371/journal.pone.0164608 · DOI
  12. Salam, 2019, Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: a systematic review of randomized trials., J Hypertens, 37, 16, 10.1097/HJH.0000000000001994 · DOI
  13. Zanchetti, 2014, Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension–Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial., J Hypertens, 32, 1888, 10.1097/HJH.0000000000000254 · DOI
  14. Lawes, 2003, Blood pressure and cardiovascular disease in the Asia Pacific region., J Hypertens, 21, 707, 10.1097/00004872-200304000-00013 · DOI · Paper page

Cited by

See all 221

Metadata

Authors
Kitagawa, K., Yamamoto, Y., Arima, H., Maeda, T., Sunami, N., Kanzawa, T., Eguchi, K., Kamiyama, K., Minematsu, K., Ueda, S., Rakugi, H., Ohya, Y., Kohro, T., Yonemoto, K., Okada, Y., Higaki, J., Tanahashi, N., Kimura, G., Umemura, S., Matsumoto, M., Shimamoto, K., Ito, S., Saruta, T., Shimada, K., & for the Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group
Venue
JAMA Neurology
Published
2019-11-01
Volume
76
Issue
11
Pages
1309
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2964879579
Cited by
221
References
5
FWCI
13.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. https://app.cochat.ai/papers/10.1001/jamaneurol.2019.2167
The paper
Kitagawa, K., Yamamoto, Y., Arima, H., Maeda, T., Sunami, N., Kanzawa, T., Eguchi, K., Kamiyama, K., Minematsu, K., Ueda, S., Rakugi, H., Ohya, Y., Kohro, T., Yonemoto, K., Okada, Y., Higaki, J., Tanahashi, N., Kimura, G., Umemura, S., . . . for the Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group. (2019). Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2019.2167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.